Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
1.
J Dermatol ; 46(4): 301-307, 2019 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-30803017

RESUMEN

Recently, the USA300 clone, which is a Panton-Valentine leukocidin (PVL)-positive clonal complex 8-staphylococcal cassette chromosome mec type IV (CC8-IV) community-acquired methicillin-resistant Staphylococcus aureus (CA-MRSA) strain, emerged in community and hospital settings in Japan. Hence, clonal types of CA-MRSA strains are predicted to be changing. Nonetheless, long-term surveillance of CA-MRSA has not been conducted in Japan. Here, we investigated the transition and current status of CA-MRSA strains isolated from outpatients with impetigo; the samples were collected between 2007 and 2016 in Kagawa, Japan. The detection rate (22.8%, 488/2139 strains) of MRSA slightly decreased in these 10 years. Molecular epidemiological analyses showed that the prevalence of the CC89-II clone, which is a typical CA-MRSA genotype of causative agents of impetigo, significantly decreased from 48.0% (48/100 strains) in 2007-2009 to 21.9% (16/73 strains) in 2013-2016. By contrast, a non-USA300 CC8-IV clone, which is a highly pathogenic CA-MRSA/J clone, significantly increased in prevalence from 9.0% (9/100 strains) to 32.9% (24/73 strains). The prevalence of PVL-positive CA-MRSA strains increased annually from 2012 (0%) to 2015 (6.7%), whereas only one of these strains turned out to be the USA300 clone. Antibiotic susceptibility data revealed that the rates of resistance to gentamicin and clindamycin among CA-MRSA strains decreased along with the decreased prevalence of the CC89-II clone and increased prevalence of the CA-MRSA/J clone. Our data strongly suggest that the clonal types and antibiotic susceptibility of CA-MRSA isolated from patients with impetigo dramatically changed during the last 10 years in Japan.


Asunto(s)
Antibacterianos/uso terapéutico , Impétigo/microbiología , Resistencia a la Meticilina/genética , Staphylococcus aureus Resistente a Meticilina/aislamiento & purificación , Infecciones Estafilocócicas/microbiología , Adolescente , Antibacterianos/farmacología , Toxinas Bacterianas/metabolismo , Niño , Clindamicina/farmacología , Clindamicina/uso terapéutico , Exotoxinas/metabolismo , Femenino , Gentamicinas/farmacología , Gentamicinas/uso terapéutico , Humanos , Impétigo/tratamiento farmacológico , Impétigo/epidemiología , Japón/epidemiología , Leucocidinas/metabolismo , Masculino , Staphylococcus aureus Resistente a Meticilina/efectos de los fármacos , Staphylococcus aureus Resistente a Meticilina/genética , Staphylococcus aureus Resistente a Meticilina/metabolismo , Pruebas de Sensibilidad Microbiana , Epidemiología Molecular , Prevalencia , Infecciones Estafilocócicas/tratamiento farmacológico , Infecciones Estafilocócicas/epidemiología
2.
Am Fam Physician ; 90(4): 229-35, 2014 Aug 15.
Artículo en Inglés | MEDLINE | ID: mdl-25250996

RESUMEN

Impetigo is the most common bacterial skin infection in children two to five years of age. There are two principal types: nonbullous (70% of cases) and bullous (30% of cases). Nonbullous impetigo, or impetigo contagiosa, is caused by Staphylococcus aureus or Streptococcus pyogenes, and is characterized by honey-colored crusts on the face and extremities. Impetigo primarily affects the skin or secondarily infects insect bites, eczema, or herpetic lesions. Bullous impetigo, which is caused exclusively by S. aureus, results in large, flaccid bullae and is more likely to affect intertriginous areas. Both types usually resolve within two to three weeks without scarring, and complications are rare, with the most serious being poststreptococcal glomerulonephritis. Treatment includes topical antibiotics such as mupirocin, retapamulin, and fusidic acid. Oral antibiotic therapy can be used for impetigo with large bullae or when topical therapy is impractical. Amoxicillin/clavulanate, dicloxacillin, cephalexin, clindamycin, doxycycline, minocycline, trimethoprim/sulfamethoxazole, and macrolides are options, but penicillin is not. Natural therapies such as tea tree oil; olive, garlic, and coconut oils; and Manuka honey have been anecdotally successful, but lack sufficient evidence to recommend or dismiss them as treatment options. Treatments under development include minocycline foam and Ozenoxacin, a topical quinolone. Topical disinfectants are inferior to antibiotics and should not be used. Empiric treatment considerations have changed with the increasing prevalence of antibiotic-resistant bacteria, with methicillin-resistant S. aureus, macrolide-resistant streptococcus, and mupirocin-resistant streptococcus all documented. Fusidic acid, mupirocin, and retapamulin cover methicillin-susceptible S. aureus and streptococcal infections. Clindamycin proves helpful in suspected methicillin-resistant S. aureus infections. Trimethoprim/sulfamethoxazole covers methicillin-resistant S. aureus infection, but is inadequate for streptococcal infection.


Asunto(s)
Antibacterianos/administración & dosificación , Manejo de la Enfermedad , Impétigo , Piel/patología , Administración Cutánea , Diagnóstico Diferencial , Salud Global , Humanos , Impétigo/diagnóstico , Impétigo/tratamiento farmacológico , Impétigo/epidemiología , Incidencia
3.
Pediatr Infect Dis J ; 31(4): 407-9, 2012 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-22189527

RESUMEN

We sought to determine the effects of maternal zinc supplementation on skin infections among infants in poor urban areas of Dhaka, Bangladesh. A double-blind, placebo-controlled, randomized trial was conducted among 199 and 221 Bangladeshi infants whose mothers were administered 30 mg daily of zinc or placebo, respectively. The mothers received zinc supplementation from 12-16 weeks' gestation until delivery, and the infants were followed up until 6 months of age. Among the infants of mothers who received zinc supplementation during the antenatal period, 10.6% had at least 1 episode of impetigo compared with 19.6% of the infants of mothers in the placebo group (P = 0.01). Infants in the treatment group had a 54% reduction in incidence rate of episodes of impetigo when compared with infants in the placebo group (P = 0.01). The effect of zinc supplementation was more pronounced among male infants (64% reduction) and intrauterine growth restricted and low birth weight infants (73% reduction) and among infants of mothers with increased parity (60% reduction) or decreased socioeconomic status (71% reduction).


Asunto(s)
Dieta/métodos , Suplementos Dietéticos , Impétigo/epidemiología , Impétigo/prevención & control , Zinc/administración & dosificación , Adulto , Bangladesh/epidemiología , Método Doble Ciego , Femenino , Humanos , Incidencia , Lactante , Recién Nacido , Masculino , Placebos/administración & dosificación , Embarazo
4.
Neonatology ; 96(1): 61-8, 2009.
Artículo en Inglés | MEDLINE | ID: mdl-19252410

RESUMEN

BACKGROUND: Carriers of Staphylococcus aureus strains can be the source of epidemic infection for patients. OBJECTIVES: A molecular epidemiological analysis of an impetigo bullosa outbreak in a neonatal ward was performed in order to determine a potential source of the infection and possible routes of subsequent spreading of the epidemic strain. METHODS: The genetic relatedness of S. aureus strains isolated from 6 neonates with epidermal lesions and from 21 staff members was verified by the pulsed field gel electrophoresis (PFGE) method. Additionally, detection of eta and etb genes of S. aureus strains using PCR was performed. RESULTS: None of the infected newborns' mothers was a carrier. Seven strains, 6 isolated from the newborns and 1 taken from a midwife, showed the same restriction pattern, i.e. type A. In the other 20 health care workers colonized with S. aureus, 3 genetic types could be distinguished, i.e. B (2), C (7) and D (2), as well as 9 strains with unique PFGE patterns. The eta gene detected in 7 strains belonged to the genetic type A; there was no etb gene in any of the 27 S. aureus isolates. CONCLUSIONS: The presence of the same genetic type A of S. aureus in the infected newborns is a factor which indicates that the impetigo bullosa was a hospital infection. A probable source of the infection was a midwife who was colonized with the same S. aureus type. She was present at the birth of the first infected newborn. Today, molecular methods are essential for prompt recognition of an epidemic and implementation of appropriate infection control strategies.


Asunto(s)
Impétigo/epidemiología , Impétigo/microbiología , Staphylococcus aureus/genética , Portador Sano/microbiología , ADN Bacteriano/análisis , Dermotoxinas/genética , Electroforesis en Gel de Campo Pulsado , Exfoliatinas/genética , Femenino , Genotipo , Humanos , Recién Nacido , Masculino , Partería , Salas Cuna en Hospital , Reacción en Cadena de la Polimerasa , Staphylococcus aureus/clasificación
5.
Lancet ; 357(9262): 1080-5, 2001 Apr 07.
Artículo en Inglés | MEDLINE | ID: mdl-11297959

RESUMEN

BACKGROUND: Infant malnutrition and mortality rates are high in less-developed countries especially in low-birthweight infants. Zinc deficiency is also widely prevalent in these circumstances. We aimed to assess the effect of daily zinc supplements given to pregnant mothers on their infants' growth and morbidity. METHODS: We did a double-blind, placebo controlled, randomised trial in 199 and 221 Bangladeshi infants whose mothers took 30 mg daily elemental zinc or placebo, respectively, from 12 to 16 weeks' gestation until delivery. Infants were followed up until 6 months of age. We obtained data for morbidity every week by mothers' recall. Infants' anthropometric measurements were done every month, and their serum zinc was assessed at 1 and 6 months of age. FINDINGS: Infants of mothers who received zinc during pregnancy had at age 6 months reduced risks compared with those in the placebo group for acute diarrhoea (risk ratio 0.84; 95% CI 0.72-0.98), dysentery (0.36; 0.25-0.84), and impetigo (0.53; 0.34-0.82). These reductions were seen in low-birthweight infants but not in those with normal birthweight. There were no differences in infant growth or serum zinc concentrations between treatment groups. INTERPRETATION: Maternal zinc supplementation during pregnancy resulted in a reduction of the health risks in Bangladeshi low-birthweight infants, although this intervention did not improve birthweight. Whether zinc should be added to usual antenatal supplements in regions with high rates of low birthweight should be reviewed.


Asunto(s)
Suplementos Dietéticos , Recién Nacido de Bajo Peso/crecimiento & desarrollo , Morbilidad , Atención Prenatal , Zinc/administración & dosificación , Antropometría , Bangladesh/epidemiología , Tos/epidemiología , Países en Desarrollo , Diarrea Infantil/epidemiología , Método Doble Ciego , Disentería/epidemiología , Femenino , Humanos , Impétigo/epidemiología , Recién Nacido de Bajo Peso/sangre , Recién Nacido , Embarazo , Infecciones del Sistema Respiratorio/epidemiología , Zinc/sangre
6.
Am J Nephrol ; 15(4): 356-60, 1995.
Artículo en Inglés | MEDLINE | ID: mdl-7573198

RESUMEN

We report here a case of type 1 mesangiocapillary glomerulonephritis as well as a case of mesangial proliferative glomerulonephritis associated with streptococcal skin infection superimposed on atopic dermatitis. Both were endemic occurrences of postinfectious glomerulonephritis developed after repeated dirty-skin treatments for atopic dermatitis performed by unauthorized individuals under unsanitary conditions. Of 20 patients who were similarly treated and subsequently admitted to our hospital because of skin infection and fever, 8 (40%) showed urinary abnormalities. Four patients had renal dysfunction with acute nephritic onset. Almost all showed a decrease in CH50 values and an increase in levels of antistreptolysin O and IgE. In the 2 cases presented here, the disease eventually regressed in association with improvement of the skin infection. Although the occurrence of postinfectious glomerulonephritis has recently become uncommon, we must take care to note urinary abnormalities as early as possible in order to prevent the progression of glomerulonephritis.


Asunto(s)
Glomerulonefritis/complicaciones , Impétigo/complicaciones , Adolescente , Terapias Complementarias , Dermatitis Atópica/terapia , Femenino , Glomerulonefritis/epidemiología , Humanos , Impétigo/epidemiología , Japón/epidemiología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA